miR‑361 enhances sensitivity to 5‑fluorouracil by targeting the FOXM1‑ABCC5/10 signaling pathway in colorectal cancer

Zhang,Luyao; Li,Bo; Zhang,Beilin; Zhang,Hua; Suo,Jian

doi:10.3892/ol.2019.10741

miR‑361 enhances sensitivity to 5‑fluorouracil by targeting the FOXM1‑ABCC5/10 signaling pathway in colorectal cancer

Authors:
- Luyao Zhang
- Bo Li
- Beilin Zhang
- Hua Zhang
- Jian Suo
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Gastrointestinal Surgery, The Third Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Physiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: August 14, 2019 https://doi.org/10.3892/ol.2019.10741
Pages: 4064-4073
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is one of most common malignancies worldwide. 5‑fluorouracil (5‑FU) is a mainstay of CRC treatment, particularly in patients with advanced stages of the disease; however, 5‑FU‑based chemotherapy is not always effective and may result in progression of the disease. The present study investigated several candidate microRNAs (miRs) in parental and 5‑FU‑resistant HCT116 and HT29 cells, and identified miR‑361 as a novel regulator of chemosensitivity. Overexpression of miR‑361 enhanced the 5‑FU susceptibility of parental and resistant HCT116 and HT29 cells in vitro. Impaired colony formation capacity and increased cell apoptosis (as determined via flow cytometry) was observed in resistant HCT116 and HT29 cells. Furthermore, forkhead box M1 (FOXM1) was identified as a target gene of miR‑361 using a dual‑luciferase reporter assay, western blotting and reverse transcription‑quantitative PCR. Additionally, FOXM1 knockdown improved the cytotoxicity of 5‑FU in resistant CRC. ATP binding cassette subfamily C members 5 and 10 (ABCC5/10) were found to be downstream effectors of miR‑361. In conclusion, miR‑361 increased chemosensitivity, at least in part, via modulation of FOXM1‑ABCC5/10. miR‑361 may serve as a potential therapeutic target for patients with CRC.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser R, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Van Cutsem E, Cervantes A, Nordlinger B and Arnold D; ESMO Guidelines Working Group, : Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25 (Suppl 3):iii1–iii9. 2014. View Article : Google Scholar : PubMed/NCBI
3	Montagnani F, Chiriatti A, Turrisi G, Francini G and Fiorentini G: A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: Improved efficacy at the cost of increased toxicity. Colorectal Dis. 13:846–852. 2011. View Article : Google Scholar : PubMed/NCBI
4	Cersosimo RJ: Management of advanced colorectal cancer, Part 1. Am J Health Syst Pharm. 70:395–406. 2013. View Article : Google Scholar : PubMed/NCBI
5	Cersosimo RJ: Management of advanced colorectal cancer, Part 2. Am J Health Syst Pharm. 70:491–506. 2013. View Article : Google Scholar : PubMed/NCBI
6	Mohelnikova-Duchonova B, Melichar B and Soucek P: FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy. World J Gastroenterol. 20:10316–10330. 2014. View Article : Google Scholar : PubMed/NCBI
7	Yu HW and Cho WC: The emerging role of miRNAs in combined cancer therapy. Expert Opin Biol Ther. 15:923–925. 2015. View Article : Google Scholar : PubMed/NCBI
8	Zhao Y and Srivastava D: A developmental view of microRNA function. Trends Biochem Sci. 32:189–197. 2007. View Article : Google Scholar : PubMed/NCBI
9	Weng W, Okugawa Y, Toden S, Toiyama Y, Kusunoki M and Goel A: FOXM1 and FOXQ1 Are promising prognostic biomarkers and novel targets of Tumor-Suppressive miR-342 in human colorectal cancer. Clin Cancer Res. 22:4947–4957. 2016. View Article : Google Scholar : PubMed/NCBI
10	Weng W, Feng J, Qin H, Ma Y and Goel A: An update on miRNAs as biological and clinical determinants in colorectal cancer: A bench-to-bedside approach. Future Oncol. 11:1791–1808. 2015. View Article : Google Scholar : PubMed/NCBI
11	Irwandi RA and Vacharaksa A: The role of microRNA in periodontal tissue: A review of the literature. Arch Oral Biol. 72:66–74. 2016. View Article : Google Scholar : PubMed/NCBI
12	Huang G, Pan J, Ye Z, Fang B, Cheng W and Cao Z: Overexpression of miR-216b sensitizes NSCLC cells to cisplatin-induced apoptosis by targeting c-Jun. Oncotarget. 8:104206–104215. 2017. View Article : Google Scholar : PubMed/NCBI
13	Du X, Liu B, Luan X, Cui Q and Li L: miR-30 decreases multidrug resistance in human gastric cancer cells by modulating cell autophagy. Exp Ther Med. 15:599–605. 2018.PubMed/NCBI
14	Zhou X, Natino D, Zhai X, Gao Z and He X: MicroRNA22 inhibits the proliferation and migration, and increases the cisplatin sensitivity, of osteosarcoma cells. Mol Med Rep. 17:7209–7217. 2018.PubMed/NCBI
15	Salendo J, Spitzner M, Kramer F, Zhang X, Jo P, Wolff HA, Kitz J, Kaulfuß S, Beißbarth T, Dobbelstein M, et al: Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a,-224,-132 and let7g. Radiothe Oncol. 208:451–457. 2013. View Article : Google Scholar
16	Ye Q, Su L, Chen D, Zheng W and Liu Y: Astragaloside IV induced miR-134 expression reduces EMT and Increases chemotherapeutic sensitivity by suppressing CREB1 signaling in colorectal cancer cell line SW-480. Cell Physiol Biochem. 43:1617–1626. 2017. View Article : Google Scholar : PubMed/NCBI
17	Tokarz P and Blasiak J: The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol. 59:467–474. 2012. View Article : Google Scholar : PubMed/NCBI
18	Li XJ, Ren ZJ and Tang JH: MicroRNA-34a: A potential therapeutic target in human cancer. Cell Death Dis. 5:e13272014. View Article : Google Scholar : PubMed/NCBI
19	Liu X, Xie T, Mao X, Xue L, Chu X and Chen L: MicroRNA-149 increases the sensitivity of colorectal cancer cells to 5-Fluorouracil by targeting forkhead box transcription factor FOXM1. Cell Physiol Biochem. 39:617–629. 2016. View Article : Google Scholar : PubMed/NCBI
20	Dabkeviciene D, Jonusiene V, Zitkute V, Zalyte E, Grigaitis P, Kirveliene V and Sasnauskiene A: The role of interleukin-8 (CXCL8) and CXCR2 in acquired chemoresistance of human colorectal carcinoma cells HCT116. Med Oncol. 32:2582015. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Betel D, Wilson M, Gabow A, Marks DS and Sander C: The microRNA.org resource:targets and expression. Nucleic Acids Res. 36((Database Issue)): D149–D153. 2008.PubMed/NCBI
23	Betel D, Koppal A, Agius P, Sander C and Leslie C: Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 11:R902010. View Article : Google Scholar : PubMed/NCBI
24	John B, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS: Human MicroRNA targets. PLoS Biol. 2:e3632004. View Article : Google Scholar : PubMed/NCBI
25	Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, Longley DB and Johnston PG: Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res. 10:2158–2167. 2004. View Article : Google Scholar : PubMed/NCBI
26	Yao Z, Bhandari A, Wang Y, Pan Y, Yang F, Chen R, Xia E and Wang O: Dihydroartemisinin potentiates antitumor activity of 5-fluorouracil against a resistant colorectal cancer cell line. Biochem Biophys Res Commun. 501:636–642. 2018. View Article : Google Scholar : PubMed/NCBI
27	Lai Z, Yan Z, Chen W, Peng J, Feng J, Li Q, Jin Y and Lin J: Hedyotis diffusa Willd suppresses metastasis in 5-fluorouracil-resistant colorectal cancer cells by regulating the TGF-β signaling pathway. Mol Med Rep. 16:7752–7758. 2017. View Article : Google Scholar : PubMed/NCBI
28	Liu B, Liu Y, Zhao L, Pan Y, Shan Y, Li Y and Jia L: Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway. Mol Carcinog. 56:2669–2680. 2017. View Article : Google Scholar : PubMed/NCBI
29	Zhao C, Zhao Q, Zhang C, Wang G, Yao Y, Huang X, Zhan F, Zhu Y, Shi J, Chen J, et al: miR-15b-5p resensitizes colon cancer cells to 5-fluorouracil by promoting apoptosis via the NF-KB/XIAP axis. Sci Rep. 7:41942017. View Article : Google Scholar : PubMed/NCBI
30	Xie T, Geng J, Wang Y, Wang L, Huang M, Chen J, Zhang K, Xue L, Liu X, Mao X, et al: FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. Oncotarget. 8:8574–8589. 2017.PubMed/NCBI
31	Hou Y, Zhu Q, Li Z, Peng Y, Yu X, Yuan B, Liu Y, Liu Y, Yin L, Peng Y, et al: The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells. Cell Death Dis. 8:e26592017. View Article : Google Scholar : PubMed/NCBI
32	Hollis M, Nair K, Vyas A, Chaturvedi LS, Gambhir S and Vyas D: MicroRNAs potential utility in colon cancer: Early detection, prognosis, and chemosensitivity. World J Gastroenterol. 21:8284–8292. 2015. View Article : Google Scholar : PubMed/NCBI
33	Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
34	Tian L, Zhao Z, Xie L and Zhu J: MiR-361-5p inhibits the mobility of gastric cancer cells through suppressing epithelial-mesenchymal transition via the Wnt/β-catenin pathway. Gene. 675:102–109. 2018. View Article : Google Scholar : PubMed/NCBI
35	Han J, Yu J, Dai Y, Li J, Guo M, Song J and Zhou X: Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway. Bosn J Basic Med Sci. 19:52–59. 2019. View Article : Google Scholar : PubMed/NCBI
36	Li R, Dong B, Wang Z, Jiang T and Chen G: MicroRNA-361-5p inhibits papillary thyroid carcinoma progression by targeting ROCK1. Biomed Pharmacother. 102:988–995. 2018. View Article : Google Scholar : PubMed/NCBI
37	Li L, Wu D, Yu Q, Li L and Wu P: Prognostic value of FOXM1 in solid tumors: A systematic review and meta-analysis. Oncotarget. 8:32298–32308. 2017.PubMed/NCBI
38	Cao S, Lin L, Xia X and Wu H: MicroRNA-761 promotes the sensitivity of colorectal cancer cells to 5-Fluorouracil through targeting FOXM1. Oncotarget. 9:321–331. 2017.PubMed/NCBI
39	Anreddy N, Patel A, Sodani K, Kathawala RJ, Chen EP, Wurpel JN and Chen ZS: PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR. Acta Pharm Sin B. 4:202–207. 2014. View Article : Google Scholar : PubMed/NCBI
40	Sun YL, Chen JJ, Kumar P, Chen K, Sodani K, Patel A, Chen YL, Chen SD, Jiang WQ and Chen ZS: Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. PLoS One. 8:e555762013. View Article : Google Scholar : PubMed/NCBI
41	Zhu Y, Yu F, Jiao Y, Feng J, Tang W, Yao H, Gong C, Chen J, Su F, Zhang Y and Song E: Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin Cancer Res. 17:7105–7115. 2011. View Article : Google Scholar : PubMed/NCBI
42	Hagmann W, Faissner R, Schnölzer M, Löhr M and Jesnowski R: Membrane drug transporters and chemoresistance in human pancreatic carcinoma. Cancers (Basel). 3:106–125. 2010. View Article : Google Scholar : PubMed/NCBI